Key Documents
Fund Summary
The ARK Genomic Revolution UCITS ETF seeks to invest in global equity securities of companies involved in the genomic revolution. These are companies that are substantially focused on or benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation. These companies may include ones across multiple sectors, such as healthcare, information technology, materials, energy and consumer discretionary. These companies may also develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and agricultural biotechnology.
Key Information
- AUM ($USD): 2,250,357
- TER: 0.75%
- ISIN: IE000O5M6XO1
- Base Code: ARKG
- SFDR Classification: Article 8
- MSCI ESG Rating: BBB
Investment Case
The plummeting costs of genomic sequencing and the rise of multiomic technologies are unlocking unprecedented opportunities in healthcare. Our journey into the molecular fabric of life itself is transforming our approach to diseases that have long evaded cure, particularly rare genetic disorders and cancer. In 2023, the medical community achieved a milestone with the first approvals for gene editing treatments for beta thalassemia and sickle cell disease in both the United States and Europe, signalling a new dawn for patients burdened by these conditions. Meanwhile, in the UK in 2022, a young leukaemia patient found hope through a pioneering T-cell therapy, marking another step forward in our battle against cancer. This genomic revolution, underpinned by innovations in AI and automation, is not merely about extending the boundaries of traditional medicine; it’s about reshaping our understanding of life, health and the potential for healing on a molecular level. As we stand on the cusp of this new frontier, the implications for patient care, biological sciences and the broader economy are profound, forecasting a future where the treatment of once-intractable diseases becomes a reality for all.
Why ARKG?
-
Exposure to Innovation
Aims for thematic multi-cap exposure to innovative elements including gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations. ARK believes the securities held in ARKG present the best risk-reward opportunities from ARK's Genomic Revolution theme. -
Growth Potential
Aims to capture long-term growth with low correlation to relative returns to traditional growth strategies and negative correlation to value strategies. -
Tool for Diversification
Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional value/growth strategies. -
Grounded in Research
Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets. -
Cost Effective
Provides a lower cost alternative to mutual funds with true active management in an Exchange Traded Fund (ETF) that invests in rapidly moving themes.
Technology Breakdown
We have identified five innovation platforms—Artificial Intelligence, Robotics, Energy Storage, Multiomic Sequencing and Public Blockchains—as the areas of technological foment creating the most meaningful convergences today. They are the emerging “General Purpose Technologies” that we believe will transform and accelerate economic growth. Within these five innovation platforms, we have identified a number of transformative technologies that are approaching tipping points as costs drop, unleashing demand across sectors and geographies and spawning more innovation.
GENOMIC REVOLUTION
Precision Therapies
Intelligent Devices
Multiomic Technologies
Next Gen Cloud
Neural Networks
Adaptive Robotics
Programmable Biology
Top 10 Holdings
Full fund holdings| Name | ISIN | Weight | CCY |
|---|---|---|---|
| TWIST BIOSCIENCE CORP COM | US90184D1000 | 9.6% | USD |
| CRISPR THERAPEUTICS AG COM CHF0.03 | CH0334081137 | 7.54% | USD |
| CAREDX INC COM | US14167L1035 | 6.31% | USD |
| RECURSION PHARMACEUTICALS INC | US75629V1044 | 5.56% | USD |
| IONIS PHARMACEUTICALS INC COM | US4622221004 | 4.94% | USD |
| INTELLIA THERAPEUTICS INC COM | US45826J1051 | 4.57% | USD |
| BEAM THERAPEUTICS INC COM | US07373V1052 | 3.85% | USD |
| NURIX THERAPEUTICS INC COM | US67080M1036 | 3.71% | USD |
| SCHRODINGER INC COM | US80810D1037 | 3.67% | USD |
| ARCTURUS THERAPEUTICS HLDGS INC COM | US03969T1097 | 3.51% | USD |
Fund Details
| Net Assets | USD 2,250,357 |
| NAV per share | USD 4.4125 |
| Shares Outstanding | 510,000 |
| Type | Active Equity ETF |
| Total Expense Ratio | 0.75% |
| Inception | 12/04/2024 |
| ISIN | IE000O5M6XO1 |
| Base Code | ARKG |
| Base Currency | USD |
| Portfolio Manager | Catherine D. Wood |
| Associate Portfolio Managers | Dan White, Nicholas Grous |
| Income Treatment | Accumulating |
| No. of holdings | 40 |
| UCITS | Yes |
| Domicile | Ireland |
| Issuer | ARK Invest UCITS ICAV |
| Promoter | ARK Invest International Ltd |
| Manager | IQ EQ Fund Management (Ireland) Limited |
| Investment Manager | ARK Investment Management LLC |
| Depositary / Custodian | Northern Trust Fiduciary Services (Ireland) Limited |
| ISA Eligible (UK) | Yes |
| SIPP Eligible (UK) | Yes |
| Reporting Fund Status (UK) | Yes |
| Equity Fund (DE) | Yes |
| SFDR Classification | Article 8 |
Registrations
- Austria
- Denmark
- Finland
- Germany
- Ireland
- Italy
- Luxembourg
- Netherlands
- Norway
- Spain
- Sweden
- United Kingdom
Listings
| Exchange | Currency | Listing Date | SEDOL | Bloomberg Ticker | RIC |
|---|---|---|---|---|---|
| Borsa Italiana | EUR | 06-May-24 | BKVDTH7 | ARKG IM | ARKG.MI |
| Deutsche Börse Xetra | EUR | 18-Apr-24 | BKVDTG6 | AAKG GY | AAKG.DE |
| CBOE Amsterdam | EUR | 19-Apr-24 | BKVDTR7 | ARKGx I2 | ARKGx.DXE |
| London Stock Exchange | USD | 19-Apr-24 | BKVDTC2 | ARKG LN | ARKG.L |
| London Stock Exchange | GBP | 19-Apr-24 | BKVDTF5 | ARCG LN | ARCG.L |
| SIX Swiss Exchange | CHF | Pending | Pending | Pending | Pending |
